Value for Money? An Analysis of Five Product-Driven M&A Deals
By Heather Cartwright & Dan Roberts
Pharma Deals Review: Vol 2017 Issue 12 (Table of Contents)
Published: 29 Dec-2017
DOI: 10.3833/pdr.v2017.i12.2292 ISSN: 1756-7874
Section: Opinion & Analysis
Fulltext:
Abstract
Big pharma has shown little appetite for large-scale M&A in recent years, but has remained willing to pay sizeable sums in order to access highly coveted near-term revenue drivers via bolt-on acquisitions...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018